Abstract. We conducted a quasi-experimental study to compare the response to meglumine antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of Brazil that were infected by two Leishmania species. Sixty-one were infected by Leishmania (Viannia) braziliensis (group B) and 57 by L. (V.) guyanensis (group G). All had a parasitologically proven diagnosis and were treated with 20 mg of pentavalent antimonial (Sb V )/kg/day given intravenously or intramuscularly for 20 days. Main outcomes were diagnosed using clinical criteria three months after treatment and patients were followed for six months. Intention-to-treat analysis showed a higher failure rate in group G (relative risk [RR] ϭ 1.5, 95% confidence interval [CI] ϭ 1.1-2.0, 2 ϭ 7.44, P ϭ 0.006). The analysis using an explanatory approach including 52 patients from group B and 49 from group G, who were regularly treated and followed for six months, showed a low cure rate (50. 8% in group B and 26.3% in group G) with a greater risk of failure in the latter group (RR ϭ 1.7, 95% CI ϭ 1.2-2.5, 2 ϭ 8.56, P ϭ 0.003). The effect of the etiologic agent remained significant after adjusting for age, disease duration, and site and number of lesions that were identified as predictors of failure in a logistic regression model. We concluded that Leishmania species constitute an important factor in predicting the outcome of cutaneous leishmaniasis treated with a pentavalent antimonial.
INTRODUCTION
Treatment of leishmaniasis has been reviewed elsewhere and is restricted to few active parenteral drugs with significant toxicity and high cost. [1] [2] [3] [4] [5] Despite some efforts to develop an oral treatment, this type of approach is not currently available. 6, 7 The situation is extremely complex for American cutaneous leishmaniasis because of the polymorphism of clinical presentations, multiple species causing the disease, and a diversity of peculiar transmission cycles in a great number of geographic areas. The main problems are related to clinical trials with poor quality design, lack of information about the species that actually caused the disease, incomplete descriptions of the clinical syndromes, and not clearly defined criteria for cure, therapeutic failure, and follow-up procedures. Those matters do not allow a reasonable interpretation of the results and limit the external validity of the trials. Pentavalent antimonial continue to be the first-choice drug and the evidence to support its use for treatment of cutaneous leishmaniasis (CL) is sometimes based on qualitative, retrospective, or uncontrolled observations and only a few controlled clinical trials. [8] [9] [10] [11] [12] [13] [14] [15] [16] There is a lack of knowledge about treatment response of CL to pentavalent antimonials in patients from Brazil and the information obtained through well conducted clinical trials is limited to some studies in patients infected with Leishmania (Viannia) braziliensis. 17, 18 The World Health Organization recommends treatment of CL due to L. (V.) braziliensis with parenteral pentavalent antimonials (20 mg of Sb V / kg/day) for 20-30 days. 19 Dose-finding clinical trials have been reported in Brazil, which suggest that the appropriate dose could be different depending on the geographic region where the disease occurs. 17 In an endemic area located in the southern region of the State of Bahia, a well-controlled trial showed that treatment duration was as important as antimony dose, with a greater failure rate observed in patients treated for 10 versus 20 days (Merchan-Hamann E, unpublished data). Based on that trial, the treatment in the basic health unit of Corte de Pedra District in Presidente Tancredo Neves, Bahia has been 20 mg of Sb V /kg/day given intravenously (IV) or intramuscularly (IM) for 20 days for CL and the same dose for 30 days for mucosal lesions, without an upper limit dose differently of recommendations of the World Health Organization. 19 This therapeutic conduct is supported by the increased efficacy and no evidence of increased toxicity with daily doses greater than 850 mg of Sb V as discussed by Herwaldt and Berman, 3 except for the recent report of frequent serious side effects in patients with visceral leishmaniasis co-infected with the human immunodeficiency virus. 20 Treatment of CL due to L. (V.) guyanensis has not been systematically studied in Brazil. Reports of successful treatment in French Guiana using pentamidine have been published, but the observations appear to be retrospectively obtained using uncontrolled procedures. 21 Experience in Colombia where L. (V.) guyanensis occurs is limited because the trials had involved mainly patients with L. (V.) panamensis infections. 16 The Ministry of Health of Brazil recommends treatment of patients with CL without special considerations of the etiologic agent involved, except for cases of mucosal lesions usually caused by L. (V.) braziliensis. 22 We conducted a quasi-experimental trial 23 to compare the response to meglumine antimoniate in two groups of patients infected by each species identifying potential prognostic factors to predict treatment failure.
MATERIALS AND METHODS
Study areas. Two geographic areas were chosen based on previous reports about predominance of L. (V.) braziliensis or L. (V.) guyanensis isolated from human cases and the possibility of support in a referral clinic specialized in the diagnosis and treatment of CL. Leishmania (V.) braziliensis infection was studied in patients from an endemic area located in the southern region of the State of Bahia (north- Sample size. The number of patients required to estimate the therapeutic failure rate was calculated for each endemic area by considering the number of CL cases registered at referral clinics during the last two years before the beginning of the trial. The estimated prevalence of therapeutic failure for both areas was 20%, with a desired precision of 10%, and ␣ ϭ 0.05. Calculations were performed using EPI Info software version 6.04 (Centers for Disease Control and Prevention, Atlanta, GA). The effective sample size was 55 and 57 patients for areas endemic for L. (V.) braziliensis and L. (V.) guyanensis, respectively. When the possibility of losses during follow-up was considered, the sample was increased by 10%. Those numbers would permit detection of differences equal or greater than 20% in cure rates between groups with ␣ ϭ 0.05 and ␤ ϭ 0.20. 25 Patients. All individuals with cutaneous ulcers who consulted the referral clinics in the periods previously described were considered as candidates. Inclusion criteria were up to six cutaneous ulcers with 2-20 weeks of evolution without previous specific treatment, an age of 8-60 years, and a positive skin test result to leishmanin. Patients with a history of leishmaniasis or concomitant mucosal involvement, patients enrolled in other research protocols, pregnant women, and those who refused to accept the diagnostic procedures, were excluded. Confirmed parasitologic diagnosis was required. 22 Parasitologic diagnosis and parasite identification. A parasitologically proven case was considered when positive results were obtained with any of the following methods: direct examinations of skin biopsy imprints obtained from the ulcer border, skin ulcer or satellite lymph node culture through a vacuum aspiratory technique, 26, 27 or successful isolation in inoculated hamsters. All isolates were identified with 23 monoclonal antibodies using an immunofluorescent technique, 28 and the electrophoretic patterns of six enzymes following previously described methods. 29 Clinical examination. Ulcers were measured with a 0.1-cm precision instrument that measured the transversal and sagittal diameters. The ulcerated area was calculated using the formula area ϭ (transversal diameter/2) ϫ (sagital diameter/2) ϫ (3.14). Patients with multiple lesions had the total ulcerated area calculated by the sum of all ulcerated lesions. Induration and erythema were not considered in evaluating lesion size. Lesions were measured by the same observer during each clinic visit until complete epithelialization was achieved.
Montenegro skin test. Antigen was prepared as previously described. 30 One hundred microliters of soluble components of L. (L.) amazonensis promastigotes, MHOM/BR/ 86/BA 125 strain containing 250 g/ml, were applied by intradermal injection on the volar surface of the left forearm and the reaction was measured after 48-72 hr using the stan-dard procedure. 31 Induration diameters Ն 5 mm were considered positive.
Treatment. Both groups were treated with a single lot of meglumine antimoniate (Glucantime; Rhodia, Sao Paulo, Brazil), 20 mg of Sb V /kg/day given IV or IM for 20 days. Meglumine antimoniate is the only available drug for routine treatment of CL in Brazil. Sodium stibogluconate produced in China was available for a short period in 1996, but the Ministry of Health stopped its distribution because increased toxicity was observed when compared with meglumine antimoniate. 18 Patients received the drug and disposable syringes and were instructed to have the medication administered at the nearest health unit. Patients were required to return the empty drug ampules and used syringes to verify protocol compliance. The same therapeutic schedule used as primary treatment or alternative treatments were prescribed when drug failure was diagnosed. Patients were removed from the study protocol for the following reasons: failure to receive the drug in a regular manner (i.e., more than 24 days required to complete the 20 prescribed doses), onset of severe adverse effects, or irregular follow-up during the threemonth-period after treatment or upon specific patient request. Toxicity monitoring was performed based on patient symptoms during each clinic visit and laboratory testing was not done.
Follow-up and outcome. Clinical evaluations were performed every 10 days during treatment and monthly thereafter for three months by only one observer for both groups. The last evaluation was six months after the 20th day of treatment. The final decision to diagnose the failure cases was supported by photographic documentation taken at each clinic visit during follow-up. Primary endpoints were defined as cure, therapeutic failure, and relapse as follows.
Cure. Patients were considered cured if complete healing, characterized by full epithelialization, absence of any inflammatory sign (including residual edema and erythema), no evidence of new lesions, and complete regression of satellite adenomegaly or lymphangitis were observed during the first three months after treatment.
Failure. Therapeutic failure was diagnosed when any of the following situations developed: incomplete healing characterized by partial epithelialization, persistent inflammatory signs despite complete epithelialization, lack of improvement, increase in the ulcerated area (Ͼ 100% compared with the size before treatment), new ulcerated lesions, or any worsening of the inflammatory process after any period of improvement during the first three months of follow-up.
Relapse. Relapse was diagnosed if any of the following conditions were met: development of inflammatory signs, with or without ulceration, in a previously cured lesion (see above criteria) or the onset of new lesions after 3-6 months of follow-up. Patients showing relapse were also diagnosed as therapeutic failures.
Drug quality. Drug osmolarity and pH were measured in a random sample of 10 ampules (each time) in July 1996, January 1997, and March 1998. The number of ampules tested was estimated based on previous studies about the stability of physico-chemical properties of meglumine antimoniate. 32 Total and trivalent antimony concentrations were measured once in January 1997 in three ampules using classical methods with some modifications. 33 Statistical analysis. We performed three different approaches to compare the treatment outcomes between groups. The first approach was an intention-to-treat analysis that included all 118 patients enrolled at the beginning of the trial and considered patients with irregular treatments and follow-ups as therapeutic failures. The second was more stringent and included the 101 patients with regular treatment and follow-up. They were considered good compliers and better represented an explanatory approach that allowed the interpretation of data in terms of effectively treated patients. The logistic regression model (LR) was developed using the data from these 101 patients, with attempts to adjust for the other prognostic factors associated with therapeutic failure in the univariate analysis. The third approach used the Kaplan-Meier method to compare time-to-failure data of the 118 initially enrolled patients. Significance tests for proportions and the relative risks (RRs) with 95% confidence intervals (CIs) were calculated using EPI Info 6.04 software. The Statistical Package for Social Sciences, version 7.5 (SPSS, Inc., Chicago, IL) was used to compare continuous variables by the Mann-Whitney U test, and to perform the Kaplan-Meier analysis of time-to-failure data. Estimation of the 95% CI for the difference between proportions was calculated following the guidelines of Gardner and Altman. 34 The significance level was fixed at P ϭ 0.05. The LR model was constructed using SPSS software. The forward stepwise LR method was used with the entry of potential prognostic factors based on the significance of the score statistic, and removal testing based on the probability of a likelihood-ratio statistic based on the maximum partial likelihood estimates. Limits of probability were 0.15 for stepwise entry and 0.20 for removal. Inclusion of interactions was considered when evidence of at least moderate significance (0.05-0.15) by the Log likelihood-ratio test was observed when the interaction was included in the model. Odds ratio estimates for the factors included in an interaction were calculated following the recommendations of Hosmer and Lemeshow using a covariance matrix. 35 
RESULTS
Groups were comparable by sex distribution: 47 (77%) of 61 patients in group B and 47 (82%) of 57 of patients in group G were males ( 2 ϭ 0.53, P ϭ 0.160). Table 2 shows comparisons regarding age, disease duration, number of ulcerated lesions, lesion size, and leishmanin skin test diameters using data from 61 and 57 patients in groups B and G, respectively. Lymphatic involvement was more frequently observed in group B (82%) than in group G patients (60%) ( 2 ϭ 7.16, P ϭ 0.007). Proportions of symptomatic ulcers were similar in both groups (90% in group B and 84% in group G, ( 2 ϭ 0.94, P ϭ 0.332).
Both groups showed low cure rates: 31 (50.8%) of 61 patients in group B and 15 (26.3%) of 57 patients in group G. The compliance rate to the therapeutic schedule was 84.2% (52 patients) and 91.2% (52 patients) for groups B and G, respectively. Fifty-three (86.9%) of 61 and 41 (71.9%) of 57 patients in groups B and G had the drug administered exclusively by the IV route. Patient losses because of irregular treatment were not significantly different between groups ( 2 ϭ 1.01, P ϭ 0.315). Median time to complete the 20 prescribed doses of antimonial in patients who had a regular treatment schedule was 21 days (interquartile range ϭ 2) and 20 days (interquartile range ϭ 0) for groups B and G, respectively. One of the 14 patients who had irregular treatment had moderate side effects that prevented normal activity. Seventy-one (68.3%) of 104 regularly treated patients had at least one of the following adverse effects: myalgias, arthralgias, anorexia, or headache. No patients in either group were noted to have severe adverse events. Fifty-two (85%) of 61 patients in group B and 49 (86%) of 57 patients of group G completed the six months of follow-up. Table 3 summarizes the results of the intention-to-treat approach and the analysis of ''compliers only'' comparing therapeutic failure rates. The analysis of time to failure data by the Kaplan-Meier method showed a significant shorter mean time to failure in group G (13.4 weeks, 95% CI ϭ 11.0-15.8; 18.7 weeks, 95% CI ϭ 16.3-21.1 for groups B and G, respectively; log rank ϭ 9.31, P ϭ 0.002) ( Figure  1 ). One hundred patients improved with treatment independently of the group, and only one patient in group B had a Ͼ100% increase in the size of the initial ulcerated area. The conditions associated with therapeutic failure are shown in Table 4 . Eight patients in group B and nine patients in group G developed new lesions during follow-up, but only two patients were diagnosed as having therapeutic failure exclusively by this criterion because the other 15 fulfilled failure criteria applied to the primary lesions during the first three months of follow-up. Among patients who developed new lesions during follow-up, four patients in group B and one patient in group G showed these lesions in a body segment different from the primary site of the ulcers. All patients who were considered as having therapeutic failure due to worsening after initial improvement, showed that outcome after completing the 20 days of treatment. Forty (90.9%) of 44 patients that worsened were characterized by relapse of inflammatory signs such as edema and erythema in the border of a epithelializated lesion, and the final decision to classify these cases as therapeutic failures was based on clinical find- ings and supported by comparing photographic documentation taken at each clinic visit. Treatment and follow-up of patients after the diagnosis of therapeutic failure were variable. Twenty patients in group B were treated with sodium stibogluconate produced in China (20 mg of Sb V /kg/day for 20 days). After at least three months of follow-up, six patients were cured, eight fulfilled criteria for therapeutic failure, two showed improvement of the inflammatory process, and four were lost of follow-up. Those with a new failure episode were treated again with sodium stibogluconate at the same dose, and in one case, pentamidine (4 mg/kg/day, nine doses every 48 hr) and two series of aminosidine (20 mg/kg/day given IM for 20 days) were given to achieve a satisfactory response. Thirty-four patients in group G were treated with different drugs (20 received meglumine antimoniate, eight were treated with three doses of pentamidine [4 mg/kg/day], and six were treated with sodium stibogluconate). After three months of follow-up, eight patients were cured (five treated with meglumine antimoniate, two treated with pentamidine, and one treated with sodium stibogluconate). Two patients showed improvement. Ten patients fulfilled failure criteria and were re-treated with pentamidine. Losses during follow-up were considerable higher in this group (14 of 34 patients). Table 5 summarizes the univariate analysis performed to identify potential risk factors for therapeutic failure. Significant associations were detected for parasite species, age, lesion number, lesion site, and disease duration. The presence of painful lesions showed moderate significance and was also tested in the LR model (Table 6 ). Age and disease 
† At least one lesion located in the lower limbs. ‡ Interaction between the parasite species and the lesion type. 
duration were included as dichotomous variables because they exhibited this behavior when quartile analysis was performed. The interaction between parasite species and lesion type was the only one with statistic significance and biological relevance to be included in the final model. Odds ratios for the different strata of the variables affected by the interaction are shown in Table 7 .
Time to achieve complete epithelialization during the first three months of follow-up was recorded as a secondary endpoint to better describe the healing process (complete epithelialization was a secondary endpoint due to the impossibility of considering this process as a synonym of cure because the frequent inflammatory signs observed around the scar at the moment that phenomenon was achieved). Complete epithelialization of the ulcers was analyzed using an approach based on the data of the 189 lesions observed in 101 patients with regular follow-up. The observation time to diagnose the phenomenon was 15 weeks beginning at the first day of treatment. Fifty (64.9%) of 77 lesions in group B patients and 53 (47.3%) of 112 lesions in group G patients healed ( 2 ϭ 5.71, P ϭ 0.017). However, 64 (83.1%) and 109 (97.3%) lesions in patients in groups B and G, respectively, achieved complete epithelialization during the first three months ( 2 ϭ 11.88, P Ͻ 0.001). Persistent inflammatory signs were frequently observed at the time complete epithelialization was achieved, precluding the possibility of considering the lesion as cured. The mean time required to achieve complete epithelialization calculated by the KaplanMeier method was 7.2 weeks (95% CI ϭ 6.2-8.2) and 3.9 weeks (95% CI ϭ 3.4-4.4) for groups B and G, respectively (log rank ϭ 35.92, P Ͻ 0.001), with censored cases corresponding to lesions that fulfilled criteria for therapeutic failure before being completely epithelializated (Figure 2) .
Measures of physico-chemical properties of meglumine antimoniate remained stable during the study period (Table  8 ).
DISCUSSION
Our data support the conclusion that the response to treatment with meglumine antimoniate is different for the parasite species studied. Low cure rates were observed in both groups. We detected a precarious response to pentavalent antimonial manifested by higher and earlier therapeutic failure in L. (V.) guyanensis-infected patients (group G), which raises issues about the need for a careful review of the recommended treatment. The same consideration could be made for L. (V.) braziliensis-infected patients (group B), who also showed a poor response. Our results suggest that clinical trials with other available drugs, especially pentamidine, are urgently needed for L. (V.) guyanensis-infected patients in Brazil. This is especially true when one considers the reported experience from Colombia 15 and French Guiana. 21 Despite the higher failure rate observed in patients infected with L. (V.) guyanensis, ulcers showed faster epithelialization (Figure 2) . The difference between groups regarding the epithelialization process remained unchanged when the analysis was restricted to lesions with an area less than 2 cm 2 . We did not measure the volume of the ulcers because of the lack of a well-standardized method. The necrotic process could be more severe in L. (V.) braziliensis infections, which cause more profound ulcerations that require a longer time to heal. We preferred to be cautious in using the approach to define group differences using the lesion as the analysis unit because the trial was planned to quantify individual outcome, but not lesion outcome.
The trial had limitations inherent to the quasi-experimental approach that defined to whom, when, and how the individuals were treated and followed, but the nature of the research prevented the use of randomized and blinded patient allocation into treatment groups as expected in a classical clinical trial. Blinding was impossible because the geographic origin of the cases clearly identify the more plausible parasite species involved. Another limitation was that the study staff did not observe the therapy being taken, but we asked patients to return the used syringes and empty ampules as a form of compliance during the 10th and 20th day visits. One advantage of the trial was the possibility of only one FIGURE 2. Cumulative estimates (Kaplan-Meier) of time-to-complete-epithelialization data for the 189 lesions observed during the 15 weeks of follow-up (''compliers only''). The y-axis represents the estimated cumulative proportion of individuals who did not achieve complete epithelialization. observer measuring the outcomes in both groups, thus reducing inter-observer variation. The initial estimation of the therapeutic failure rate (20%) was incorrect. This estimation was based on previous studies in L. (V.) braziliensis-infected patients in Corte de Pedra, Bahia (Merchan-Hamann E, unpublished data), and the potential explanations for the greater failure rate observed would be the use of more stringent criteria defining clinical cure and the restricted three months of observation to establish the main treatment outcome. Nevertheless, the number of patients treated with the same dose in that trial was small (21 patients).
A significant number of patients were not enrolled in the study (53.3% and 60.2% for Corte de Pedra and Manaus regions, respectively), raising the possibility of a non-representative sample as a potential cause of the observed differences. A retrospective analysis of patients who attended the clinics where our study was performed during the 1995-1997 period (1,298 patients in Corte de Pedra and 2,152 patients in Manaus) showed that the samples enrolled were similar to those populations when compared by age, sex, number of lesions, and disease duration. The inclusion criteria in this study could lead to selection bias because of the exclusion of patients with a negative skin test result. However, we observed that during the entry period only three patients from the endemic area in Corte de Pedra were excluded by this criterion, showing that a negative leishmanin skin test result is very rare. Another possible selection bias could be related to exclusions by the presence of more than six ulcers, but the number of patients excluded by this criterion was comparable in both groups. Multiple lesions in L. (V.) braziliensis-infected patients could correspond to the disseminated form that represents a special syndrome with peculiar response to treatment due to a particular immunopathologic profile. 36 Six of eight patients excluded for that reason in Corte de Pedra showed the classical disseminated disease, but this syndrome was not observed in Manaus, suggesting that this type of clinical presentation is rare in the region. The more stringent selection criteria applied to patients from Manaus region, related to parasite isolation and identification, were justified because the possibility of sympatric circulation of L.
(V.) braziliensis and L. (V.) guyanensis in that area (as demonstrated by the isolation of L. (V.) braziliensis from two patients).
The influence of other species such as Leishmania (L.) amazonensis modifying the response observed in the Corte de Pedra sample seems unlikely due to the recognized easier isolation in culture and hamsters and the rarity of isolation reports of that species in the region. 24, 37 The effect of spontaneous cure on outcome were properly avoided by exclusion of patients with more than 20 weeks of disease duration and the use of a three-month observation period to diagnose cure or therapeutic failure. This phenomenon has been described in a smaller group of patients from Corte de Pedra 38 and in one patient from French Guiana after a prolonged observation of more than 12 months. 39 The use of the same lot of pentavalent antimonial to treat both groups precludes the interpretation of the observed differences based on drug variability. Both osmolarity and pH remained stable during the study period and a very low concentration of trivalent antimony was identified in a limited sample. Variations in physico-chemical properties throughout the study were smaller than the differences that have been observed between lots (Romero GAS, unpublished data) and osmolarity and pH appear to be stable characteristics that are not affected by storage temperature. 32 High osmolarity has been recently associated with severe toxicity of antimonial compounds in patients with visceral leishmaniasis in India, but there is no information about the relative efficacy of lots with different osmolarity levels. 40 A relatively inactive lot of drug cannot be excluded as the cause of the low cure rates observed in both groups.
The effect of parasite species on outcome showed that it remains significantly associated after the inclusion of age, disease duration, lesion size, and lesion type in the LR model. Despite the moderate statistic significance of the associ-ation between the lesion type and the main endpoint, it was included in the model because its biologic relevance reflecting the disease extension, and this strategy was very useful by allowing the exploration of the interaction between this variable and the parasite species (situation when the association between the risk or prognostic factor and the outcome variable differs or depends in some way on the level of the covariate, 35 guyanensis may be related to drug resistance that could be a naturally acquired condition in Leishmania, and has been associated at least partially with poor response to treatment, 41 or special characteristics of the host-parasite relation that remain obscure. The leishmanin skin test revealed that L. (V.) guyanensis induced a delayed immune response similar to that observed during disease caused by L. (V.) braziliensis, but the test does not reveal all the potential complexity of the host response to the infection. It is important to note that patients with mucosal disease due to L. (V.) braziliensis show a greater response to leishmanin when compared with patients with CL, but this is not predictive of a better therapeutic outcome. 42 Poor prognosis observed in older patients is hard to explain. Younger patients may show more efficient healing, but the Kaplan-Meier analysis of the time to achieve complete epithelialization was not affected by age. Conversely, older individuals could be more exposed to the parasite, modulating the immune response that would worsen the prognosis when the infection is manifested as clinical disease. Against the last hypothesis is the evidence of at least a protective immune profile after acute infection, 43, 44 and the rarity of probable episodes of re-infection in patients who remain living in the endemic area of the Bahia State. 45 Differences due to age could not be attributed to antimony dose because it was adjusted by weight without a maximum upper daily dose, thus avoiding the possibility of relatively smaller doses being administered to older patients. There was no difference in failure rate between patients who received 850 mg/day or more of pentavalent antimony.
It was surprising that individuals with shorter disease duration had worse prognosis. Because early treatment of infectious diseases has been traditionally accepted as essential to good clinical practice, our finding could be an important observation. The complex host-parasite relation is a dynamic process during CL, and studies in patients infected with L. (V.) braziliensis showed that during early disease the lymphoproliferative response to Leishmania antigens and production of interferon-␥ is lower, with predominant production of interleukin-10, when compared with the profile observed in patients with disease of a longer duration. 46 These data, along with our findings, suggest that early treatment does not represent an advantage at least during the first four weeks of disease, and that a better understanding of the treatment effects on early immunologic response is required.
The presence of at least one lesion in a lower limb was identified as a favorable prognostic factor. Lower limb ulcers have been considered a complicating factor that delays healing (Luján LV and others, unpublished data). Our analysis of the secondary endpoint of complete epithelialization showed that lower limb lesions took more time to heal compared with other lesion sites, in contrast with the higher cure rate. The study of this factor as a predictor of good prognosis deserves special attention in future trials.
We have clearly demonstrated that the therapeutic response to antimonials in patients with CL depends on the parasite species. This emphasizes the need for a speciesbased approach to better address therapeutic issues, especially, when sympatric circulation of multiple species occurs. Identification of prognosis-independent predictors is relevant not only for adjusting the procedure, but to create a reference scenario for future trials. Our data offer the possibility of planning the validation of prognostic factors in a greater number of patients using a species-based approach. The potential use of prognostic factors to modify treatment strategies should be considered with regard to issues such as the ideal time to diagnose cure or failure in patients with poor prognosis. Due to the lack of good prophylactic tools against CL, effective treatment deserves special attention among control measures, and our results raised very interesting therapeutic practicalities that may help to develop better strategies in the future. Our results of treatment of cases who showed therapeutic failure are incomplete and do not allow conclusions because significant losses occurred during follow-up. However, it is important to pay attention to the difficulties faced by practitioners working in endemic areas in successfully treating those patients who failed to respond to a standard regimen of meglumine antimoniate. A prolonged follow-up needed to achieve results could be an important drawback for any treatment schedule with antimonials or other drugs. As we observed, the patient compliance in making subsequent visits to health clinics were substantially diminished by long-term follow-up. Modest results obtained in patients infected with L. (V.) braziliensis who were retreated with sodium stibogluconate do not encourage the use of a more prolonged course of antimonial as an appropriate strategy to solve this problem. The experience of treatment of mucosal leishmaniasis in Peru with a 40-day regimen of sodium stibogluconate produced similar results when compared with a 28-day standard regimen, and showed that a longer course of antimonial did not improve the cure rate. 47 Currently, we ignore the effect of the spontaneous healing process in patients who are re-treated after a more prolonged disease when spontaneous cure could be observed more frequently. 38 A definite response regarding the usefulness of a second series of antimonial should be obtained in a placebocontrolled trial. The use of modulation of the immune response should be explored based on recent experiences that showed in a limited number of patients a better outcome in patients treated with granulocyte macrophage colony-stimulating factor plus sodium stibogluconate, but the high cost of such strategies must be considered. 48 Finally, well-designed trials with new drugs, such as miltefosine (ASTA Medica AG, Frankfurt, Germany) and sequential or combined use of conventional drugs should be encouraged.
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